Abstract
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Neuropathologically, the aggregation of misfolded proteins is a major hallmark of many 
55
Previous studies suggest that disrupted protein homeostasis in the endoplasmic reticulum (ER) and 
64
Advances in next generation sequencing technology have contributed substantially to our understanding of the genetics of AD. In recent years, studies using whole exome sequencing (WES) and whole genome 
120
In our discovery set, we used a family based analysis to identify candidate genes from the eight families.
121
Each family was analyzed separately to identify the candidate variants in their respective family. We
122
focused on shared variants among the affected family members which resulted in an amino acid change.
123
Subsequently, variants with a frequency of 0.5% or lower in 1000 genomes, NHLBI Exome Sequencing 
140
The variant rs147458427 (p.R240H) was genotyped using TaqMan SNP Genotyping Assays and
141
genotypes of rs147458427 were determined using TaqMan Allelic discrimination. 
179
We used Mann-Whitney U test to examine the difference between AD EIF2AK3 carriers and non-carriers.
180
All tests are two-sided significant, and a p-value below 0.05 was assumed as being statistically 
208
The first EIF2AK3 variant, p.R240H (rs147458427), was heterozygous in four affected individuals 
247
All elderly non-demented controls showed a low to moderate degree of pPERK staining in the 248 hippocampus. EIF2AK3 carriers had significantly more positive staining than non-demented controls in 249 the hippocampus (p=0.04) and temporal region (p=0.03). For peIF2α, a trend for more positive staining 250 was only observed in the hippocampus of EIF2AK3 carriers compared to non-demented controls
251
(p=0.07). We found no difference in all examined regions when comparing EIF2AK3 carriers with AD non- Figure 2) . 
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281
The potential significance of EIF2AK3 variants in our families also lies in the fact that PERK is a 
300
The increase of PERK-eIF2α signaling in the EIF2AK3 carriers is supported by the more positive staining 301 of pPERK and peIF2α compared to non-demented controls, indicating an increased activation of UPR.
302
This increased UPR has also been observed in AD and PSP patients in previous studies (Hoozemans et 
308
The main limitation of our study is the family-based analysis used to identify the candidate genes; we only 309 selected genes containing rare variants in at least two families for follow-up. We cannot rule out the 
322
In conclusion, our study showed that rare variants in EIF2AK3 may be associated with an increased risk Number of patients and controls included from each family. Cases are the total number of included patients with Alzheimer's disease and patients with mild cognitive impairment. Controls contains the total number of included individuals without subjective of objective memory impairment during the last visit. Age at onset is the mean age of first disease onset of all included cases, and the age at last visits is the mean age of all included controls. Age at onset and age at last visits in years. AD, Alzheimer's disease; WES, individuals selected for whole exome sequencing; NA, not available M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT Immunohistochemical staining of pPERK and peIF2α in the AD cases with EIF2AK3 mutations. Activated pPERK and peIF2α was found in the hippocampus and temporal regions (A-F). High numbers of pPERK stained cells were observed in the cornu ammonis (A) and subiculum (B) of the hippocampus, and lesser numbers were found in the temporal cortex (C). Abundant neurons with peIF2α staining were also found in the hippocampus (D), and a moderate number of stained cells were found in the frontal cortex (E). Cytoplasmic peIF2α staining is punctate shaped (F), and is similar to the pPERK staining (B). Scale bars have been added to the figures.
